What is a lower-cost alternative to the Trellegy (umeclidinium/vilanterol) inhaler for an adult with COPD?

Cost-Effective Alternatives to Trellegy for COPD

For most patients with COPD currently on Trellegy (a triple therapy inhaler), switching to a dual bronchodilator combination like umeclidinium/vilanterol (LAMA/LABA) or tiotropium alone represents the most cost-effective alternative, unless you have severe disease with frequent exacerbations (≥2 moderate or ≥1 severe exacerbation per year) or FEV1 <50% predicted.

Understanding What Trellegy Contains

Trellegy is a triple therapy containing:

• Fluticasone furoate (inhaled corticosteroid/ICS)
• Umeclidinium (long-acting muscarinic antagonist/LAMA)
• Vilanterol (long-acting beta-agonist/LABA)

1

Step-by-Step Approach to Finding Cheaper Alternatives

Step 1: Determine If You Actually Need Triple Therapy

You likely need triple therapy (and Trellegy may be appropriate) if you have ALL of the following:

• FEV1 <50% predicted (or <60% in some guidelines)
• ≥2 moderate exacerbations OR ≥1 hospitalization for COPD in the past year
• Persistent symptoms despite dual bronchodilator therapy
• High symptom burden (mMRC ≥2 or CAT score ≥10)

2, 3

If you DON'T meet these criteria, you can likely step down to less expensive therapy.

Step 2: Choose Your Alternative Based on Disease Severity

For Mild-to-Moderate Disease (FEV1 >60% or minimal symptoms):

Single long-acting bronchodilator monotherapy:

• Tiotropium (LAMA) - generic available, significantly cheaper
• OR umeclidinium (LAMA)
• OR a long-acting beta-agonist alone

These are appropriate for symptomatic patients who don't have frequent exacerbations 4. The guidelines support that most patients with moderate disease can be controlled on a single drug 4.

For Moderate-to-Severe Disease Without Frequent Exacerbations:

Dual bronchodilator therapy (LAMA/LABA combination):

• Umeclidinium/vilanterol - This is essentially Trellegy minus the steroid component
• Tiotropium + a separate LABA
• Other LAMA/LABA combinations

This approach provides superior bronchodilation compared to monotherapy and is recommended as an alternative choice across multiple European guidelines 2. Real-world data shows umeclidinium/vilanterol has lower costs and better adherence compared to tiotropium alone 5, with cost savings of approximately £690-1336 per year in UK analyses 6.

For Severe Disease With Frequent Exacerbations:

If you truly need triple therapy, consider:

• Budesonide/glycopyrronium/formoterol - Often less expensive than Trellegy
• Generic ICS/LABA combinations (fluticasone/salmeterol or budesonide/formoterol) + separate LAMA

Recent cost-effectiveness analyses suggest budesonide-based triple therapy may be more cost-effective than fluticasone-based options in some settings 7, though clinical outcomes appear similar 8.

Step 3: Consider the ICS Component Carefully

Important caveat about inhaled corticosteroids (ICS):

The ICS component in Trellegy increases pneumonia risk 2, 1. Guidelines across Europe recommend ICS only for:

• Patients with FEV1 <50-60% predicted AND
• ≥2 exacerbations per year despite optimal bronchodilator therapy
• OR patients with asthma-COPD overlap syndrome

2

If you don't meet these criteria, removing the ICS (stepping down to dual bronchodilator therapy) may actually improve your safety profile while reducing costs.

Practical Cost-Saving Strategies

Immediate Options:

1. Switch to umeclidinium/vilanterol dual therapy - Removes the steroid, maintains dual bronchodilation, significantly cheaper 6, 9
2. Switch to tiotropium monotherapy - Generic available, lowest cost option for appropriate patients 5
3. Use separate inhalers - Generic fluticasone/salmeterol + generic tiotropium may be cheaper than single-inhaler triple therapy

Device Considerations:

Metered-dose inhalers (MDIs) are the cheapest delivery devices 4. If you can use an MDI correctly with a spacer, this is more cost-effective than dry powder inhalers or nebulizers.

Common Pitfalls to Avoid

Don't assume you need triple therapy indefinitely. Many patients are started on triple therapy during exacerbations but can be stepped down once stable. The 2023 Canadian guidelines emphasize that triple therapy should be reserved for high-risk patients 3.

Don't stop ICS abruptly if you've been on it long-term. If stepping down from Trellegy, wean the ICS component gradually to avoid adrenal suppression 1.

Don't confuse COPD with asthma. If you have asthma-COPD overlap, you likely do need the ICS component and different considerations apply 2.

Evidence Quality Note

The strongest evidence supports LAMA monotherapy or LAMA/LABA dual therapy for most COPD patients 10, 11, 12. The superiority of triple therapy is primarily demonstrated in patients with severe disease and frequent exacerbations 3. Cost-effectiveness data consistently shows dual bronchodilator therapy provides better value for patients without frequent exacerbations 6, 9, 13.